Sign In
Buy LEGN
$35.98
-0.300 (-0.83%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Legend Biotech Corporation - LEGN
07:35pm, Monday, 18'th Dec 2023
NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation ("Legend" or the "Company") (NASDAQ: LEGN). Such investors are adv
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
09:46am, Wednesday, 29'th Nov 2023
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
09:46am, Monday, 20'th Nov 2023
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
Legend Biotech highlights Novartis deal worth up to $1.11BN alongside 3Q results
07:18am, Monday, 20'th Nov 2023
Legend Biotech Corporation (NASDAQ:LEGN) highlighted an exclusive license agreement struck with Novartis AG (ADR) (NYSE:NVS) worth up to $1.11 billion as it released third-quarter results. Under the
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
12:02pm, Tuesday, 14'th Nov 2023
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
08:16am, Thursday, 09'th Nov 2023
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
Legend Biotech: Working On Supply Issues
08:10pm, Monday, 21'st Aug 2023
Legend Biotech's Carvykti has shown improved uptake in the second quarter. The company aims to reach an annualized capacity of 10,000 doses of Carvykti by the end of 2025. Reaching the late 2025 goal
Why Earnings Season Could Be Great for Legend Biotech (LEGN)
10:09am, Monday, 14'th Aug 2023
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
08:39am, Monday, 14'th Aug 2023
We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.
Top 5 Stocks Set to Beat on Earnings Next Week
09:15am, Thursday, 10'th Aug 2023
We have narrowed our search to five stocks that are set to declare earnings results next week. These are: LEGN, TJX, WMT, ONON, BILL.
3 Biotech Stocks That Analysts Are Drooling Over
06:57pm, Monday, 07'th Aug 2023
With everyone being an expert these days, the concept of top analyst biotech picks might seem suspect at first glance. While we depend on Wall Street's spectrum of expert guidance to establish a frame
Legend Biotech shares gain on multiple-myeloma drug sales
08:23am, Thursday, 20'th Jul 2023
Shares of Legend Biotech Corp. LEGN, -1.00% gained 3.7% premarket on Thursday after the company said its multiple myeloma therapy Carvykti, a collaboration with Johnson & Johnson JNJ, -0.20%, generate
Legend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded Use
09:48am, Wednesday, 07'th Jun 2023
Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with relapsed and lenalidomide-refractory multiple myeloma. Stock rises 4% following the news.
Legend Biotech Announces Participation in Upcoming Investor Conferences
04:01pm, Friday, 02'nd Jun 2023
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-
